PF-Atlas › Clinical Trials › NCT00287729

Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Pirfenidone · Phase 3

Registry ID
NCT00287729
Phase
Phase 3
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Genentech, Inc.
Start
2006-04
Enrollment
344
Locations
1

About this trial

The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.

View NCT00287729 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT01504334Pirfenidone — NCT02932566Pirfenidone — NCT00287716
Medical disclaimer. This page summarizes public trial data for NCT00287729 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.